Pharmacy Times July 18, 2022

Maker of Sensodyne, Advil, and TUMS becomes one of the world’s leading independent consumer health companies.

Today, Haleon (LSE/NYSE: HLN) launches as an independent company 100% focused on consumer health, completing its demerger from GSK. The newly listed business is driven by its purpose todeliver better everyday health with humanity.

Trading commenced on Monday on the London Stock Exchange (LSE), with Brian McNamara, CEO of Haleon, leading the opening ceremony to signal the start of trading. Trading on the New York Stock Exchange (NYSE) is set to follow1 with a similar market-opening event taking place on Wednesday, July 20, 2022.

Haleon has a world-class portfolio of brands including Advil, Centrum, Sensodyne, Robitussin, and TUMS and will continue to develop category...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Digital Health, Patient / Consumer, Provider, Technology, Wellness
Related Articles:
Sibionics Blood Glucose Sensor: Review
Dexcom invests $75M in Ōura, agrees to integrate smart rings and CGMs
UPMC, Vanderbilt join Aegis Ventures in digital consortium
Digital Medicine Society Launches Resources to Navigate Global Digital Health Regulatory Pathways
Election Implications for Telehealth, Health Equity, AI and Life Sciences

Share This Article